Where Will Athersys Inc (ATHX) Stock Go Next After It Is Lower By 10.43% in a Week?

Friday, November 19, 2021 10:02 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Athersys Inc (ATHX) Stock Go Next After It Is Lower By 10.43% in a Week?

The market has been down on Athersys Inc (ATHX) stock recently. ATHX gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Athersys Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ATHX!

See Full ATHX Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With ATHX Stock Today?

Athersys Inc (ATHX) stock is lower by -8.84% while the S&P 500 has risen 0.06% as of 10:01 AM on Friday, Nov 19. ATHX is down -$0.10 from the previous closing price of $1.13 on volume of 552,478 shares. Over the past year the S&P 500 has risen 31.94% while ATHX is down -33.55%. ATHX lost -$0.41 per share in the over the last 12 months.

More About Athersys Inc

Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is a unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants. Click Here to get the full Stock Report for Athersys Inc stock.